Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
With both SP142 and 22C3, we identified an intermediate IHC PD-L1 group within TNBCs that was supported on the molecular level. Any PD-L1 IHC expression, even though it is < 1, tended to have positive prognostic impact. We suggest that the generally accepted threshold of PD-L1 IHC positivity in TNBC should be investigated further. The Swedish Cancerome Analysis Network - Breast (SCAN-B) study was retrospectively registered 2nd Dec 2014 at ClinicalTrials.gov; ID NCT02306096.
Authors
- Johan Hartman (ORCID: https://orcid.org/0000-0002-6500-8527)
- Susann Ullén (ORCID: https://orcid.org/0000-0003-4854-9230)
- Emma Niméus (ORCID: https://orcid.org/0000-0003-0262-9083)
- Gudbjörg Sigurjonsdottir
- Fredrika Killander (ORCID: https://orcid.org/0000-0001-6266-0459)
- Ana Bosch (ORCID: https://orcid.org/0000-0003-0666-5946)
- Anna Ehinger (ORCID: https://orcid.org/0000-0001-9225-7396)
- Karin Leandersson (ORCID: https://orcid.org/0000-0001-8254-3137)
- Johan Staaf (ORCID: https://orcid.org/0000-0001-5254-5115)
- Tommaso De Marchi (ORCID: https://orcid.org/0000-0002-4845-1084)
Institutions
- Karolinska University Hospital (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Medicon Village (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1007/s10549-024-07561-x
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Lunds Universitet